Schonfeld Strategic Advisors LLC boosted its holdings in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 1,001.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,060 shares of the company's stock after buying an additional 29,149 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Encompass Health were worth $2,961,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Encompass Health by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock valued at $960,817,000 after buying an additional 138,196 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Encompass Health by 3.3% in the 4th quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock valued at $511,273,000 after purchasing an additional 176,135 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Encompass Health by 6.0% in the 4th quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company's stock valued at $191,799,000 after acquiring an additional 117,617 shares during the period. FMR LLC lifted its stake in Encompass Health by 0.8% during the 4th quarter. FMR LLC now owns 1,973,846 shares of the company's stock worth $182,285,000 after acquiring an additional 15,831 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Encompass Health by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company's stock worth $155,176,000 after buying an additional 6,164 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other Encompass Health news, insider Elissa Joy Charbonneau sold 4,279 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total transaction of $498,974.19. Following the completion of the transaction, the insider now owns 11,958 shares in the company, valued at approximately $1,394,422.38. This trade represents a 26.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the sale, the chief accounting officer now owns 69,164 shares of the company's stock, valued at $6,798,129.56. This represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,321 shares of company stock valued at $2,142,452. 2.00% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the company. William Blair reiterated an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. StockNews.com downgraded shares of Encompass Health from a "buy" rating to a "hold" rating in a report on Saturday, May 3rd. UBS Group upped their target price on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Truist Financial reaffirmed a "buy" rating and set a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Finally, Royal Bank of Canada increased their price target on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, April 28th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $120.86.
View Our Latest Analysis on Encompass Health
Encompass Health Price Performance
NYSE EHC traded down $1.35 during trading hours on Thursday, reaching $116.13. 652,343 shares of the company's stock were exchanged, compared to its average volume of 686,904. Encompass Health Co. has a one year low of $82.74 and a one year high of $125.74. The stock has a market cap of $11.70 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The firm has a fifty day moving average of $102.75 and a 200-day moving average of $99.64.
Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.18. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The firm's revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.12 EPS. On average, equities research analysts predict that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.
Encompass Health Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.59%. Encompass Health's dividend payout ratio is currently 14.05%.
Encompass Health Profile
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Further Reading
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
